The nation of Zimbabwe has rejected a major American healthcare agreement valued at $367m (272 million pounds) over five years due to Washington's request for sensitive data.
This move came to light after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later explained that the United States was demanding access to biological samples for scientific study and profit while refused to guarantee the benefits from any future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further dialogue to find a deal suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Implications
This rejection follows a similar case in neighbouring Kenya, where a court halted a similar health funding agreement following concerns were filed about the security of Kenyans' health data.
After returning to office recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government agreements to boost openness and accountability.
As per reports, Sixteen nations in Africa have so far signed similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent promise of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Effectively, our country would provide the raw materials for medical research without any assurance that the end products would be accessible to our people should a future health crisis arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems already set up via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This framework is designed to guarantee that when a nation provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how subsequent collaboration might be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but recommended that talks need to persist given that a large portion of the country's HIV programmes relied on foreign aid.
"Where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," the group commented.
The halted deal highlights the complex debate between accepting vital international aid and protecting national sovereignty in an increasingly data-driven world.